HIV and AIDS: Looking ahead

Nature Medicine

Volumn 9, Issue 7, 2003, Pages 887-891

  Weiss, Robin A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE TRANSMISSION; GENOME; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INFECTION RISK; MEDICAL RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AFRICA; BIOMEDICAL RESEARCH; EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV-1; HUMANS; OPPORTUNISTIC INFECTIONS; UNITED STATES; VARIATION (GENETICS); VIRAL PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0038717544     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0703-887     Document Type: Review

References (58)

1. Weiss, R.A. Gulliver's travels in HIVland. Nature 410, 963-967 (2001).
2. Fields, B.N. AIDS: time to turn to basic science. Nature 369, 95-96 (1994).
3. Barré-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871 (1983).
4. Vilmer, E. et al. Isolation of new lymphotropic retrovirus from two siblings with haemophilia B, one with AIDS. Lancet 1, 753-757 (1984).
5. Ellrodt, A. et al. Isolation of human T-lymphotropic retrovirus (LAV) from Zairian married couple, one with AIDS, one with prodromes. Lancet 1, 1383-1385 (1984).
6. Montagnier, L. et al. A new type of retrovirus isolated from patients presenting with lymphadenopathy and acquired immune deficiency syndrome: structural and antigenic relatedness with equine infectious anaemia virus. Ann. Virol. 135E, 119-134 (1984).
7. Wain Hobson, S., Sonigo, P., Danos, O., Cole, S. & Alizon, M. Nucleotide sequence of the AIDS virus, LAV. Cell 40, 9-17 (1985).
8. Gallo, R.C. et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224, 500-503 (1984).
9. Levy, J.A. et al. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225, 840-842 (1984).
10. Fauci, S.A. HIV and AIDS: 20 years of science. Nat. Med. 9, 839-843 (2003)
11. Stevenson, M. HIV-1 pathogenesis. Nat. Med. 9, 853-860 (2003)
12. Pomerantz, R.J. & Horn, D.L. 20 years of therapy for HIV-1 infection. Nat. Med. 9, 867-873 (2003)
13. Serwadda, D. et al. Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet 2, 849-852 (1985).
14. Buvé, A. et al. Multicentre study on factors determining differences in rate of spread of HIV in sub-Saharan Africa: methods and prevalence of HIV infection. AIDS 15 (suppl. 4), S5-S14 (2001).
15. Gisselquist, D., Potterat, J.J., Brody, S. & Vachon, F. Let it be sexual: how health care transmission of AIDS in Africa was ignored. Int. J. STD AIDS 14, 148-161 (2003).
16. Drucker, E., Alcabes, P.G. & Marx, P.A. The injection century: massive unsterile injections and the emergence of human pathogens. Lancet 358, 1989-1992 (2001).
17. Joint United Nations Programme on HIV/AIDS (UNAIDS). Expert group stresses that unsafe sex is primary mode of HIV transmission in Africa (UNAIDS, Geneva, 2003).
18. Walker, P.R., Worobey, M., Rambaut, A., Holmes, E.C. & Pybus, O.G. Epidemiology: sexual transmission of HIV in Africa. Nature 422, 679 (2003).
19. Valdiserri, R.O., Ogden, L.L. & McCray, E. Accomplishments in HIV prevention science: implications for stemming the epidemic. Nat. Med. 9, 881-886 (2003)
20. Weiss, H.A., Quigley, M.A. & Hayes, R.J. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 14, 2361-2370 (2000).
21. Joint United Nations Programme on HIV/AIDS (UNAIDS). Male circumcision: current epidemiological and field evidence (UNAIDS, Geneva, 2003).
22. Pope, M. & Haase, A.T. HIV-1 transmission, acute infection, and the quest for strategies to prevent infection. Nat. Med. 9, 847-852 (2003)
23. Igakura, T. et al. Spread of HTLV-1 between lymphocytes by virus-induced polarization of the cytoskeleton. Science 299, 1713-1716 (2003).
24. Jung, A. et al. Multiply infected spleen cells in HIV patients. Nature 418, 144 (2002).
25. Cowan, S. et al. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci. USA 99, 11914-11919 (2002).
26. Hatziioannou, T., Cowan, S., Goff, S.P., Bieniasz, P.D. & Towers, G.J. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22, 385-394 (2003).
27. Reeves, J.D. & Doms, R.W. Human immunodeficiency virus type 2. J. Gen. Virol. 83, 1253-1265 (2002).
28. Sigurdsson, B., Thormar, H. & Palsson, P.A. Cultivation of visna virus in tissue culture. Arch. Virusforschung 10, 430-443 (1960).
29. Weiss, R.A. Lentivirus tropism and pathogenesis. Immunol. Lett. 66, 3-5 (1999).
30. Sala, M. & Wain-Hobson, S. Are RNA viruses adapting or merely changing? J. Mol. Evol. 51, 12-20 (2000).
31. Korber, B. et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Brit. Med. Bull. 58, 19-42 (2001).
32. Perelson, A.S. Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2, 28-36 (2002).
33. Korber, B. et al. Timing the ancestor of the HIV-1 pandemic strains. Science 288, 1789-1796 (2000).
34. Lemey, P. et al. Tracing the origin and history of the HIV-2 epidemic. Proc. Natl. Acad. Sci. USA 100, 6588-6592 (2003).
35. Hahn, B.H., Shaw, G.M., De Cock, K.M. & Sharp, P.M. AIDS as a zoonosis: scientific and public health implications. Science 287, 607-614 (2000).
36. Takehisa, J. et al. Human immunodeficiency virus type 1 intergroup (M/O) recombination in Cameroon. J. Virol. 73, 6810-6820 (1999).
37. Kaye, J.F. & Lever, A.M. Nonreciprocal packaging of human immunodeficiency virus type 1 and type 2 RNA: a possible role for the p2 domain of Gag in RNA encapsidation. J. Virol. 72, 5877-5885 (1998).
38. McMichael, A.J. & Hanke, T. HIV vaccines 1983-2003. Nat. Med. 9, 874-880 (2003)
39. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
40. Richman, D.D., Wrin, T., Little, S.J. & Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100, 4144-4149 (2003).
41. Sheehy, A.M., Gaddis, N.C., Choi, J.D. & Malim, M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 (2002).
42. O'Brien, S.J. & Moore, J.P. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol. Rev. 177, 99-111 (2000).
43. Gonzalez, E. et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1α: impact on the epidemiology of the HIV-1 pandemic. Proc. Natl. Acad. Sci. USA 98, 5199-5204 (2001).
44. French, N. et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 355, 2106-2111 (2000).
45. Subramaniam, K.S., Segal, R., Lyles, R.H., Rodriguez-Barradas, M.C. & Pirofski, L.A. Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J. Infect. Dis. 187, 758-768 (2003).
46. Moss, J.W., Clements, C.J. & Halsey, N.A. Immunization of children at risk of infection with human immunodeficiency virus. Bull. World Health Organ. 81, 61-70 (2003).
47. Bartlett, J.G. Smallpox vaccination and patients with human immunodeficiency virus infection or acquired immunodeficiency syndrome. Clin. Infect. Dis. 36, 468-471 (2003).
48. Redfield, R.R. et al. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316, 673-676 (1987).
49. Boshoff, C. & Weiss, R.A. AIDS-related malignancies. Nat. Rev. Cancer 2, 373-382 (2002).
50. Wald, A. & Link, K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J. Infect. Dis. 185, 45-52 (2002).
51. Mbopi-Keou, F.X. et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J. Infect. Dis. 182, 1090-1096 (2000).
52. Tilimann, H.L. et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N. Engl. J. Med. 345, 715-724 (2001).
53. Xiang, J. et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N. Engl. J. Med. 345, 707-714 (2001).
54. Watt, G. et al. HIV-1 suppression during acute scrub-typhus infection. Lancet 356, 475-479 (2000).
55. Watt, G., Kantipong, P. & Jongsakul, K. Decrease in human immunodeficiency virus type 1 load during acute dengue fever. Clin. Infect. Dis. 36, 1067-1069 (2003).
56. Walsh, P.D. et al. Catastrophic ape decline in western equatorial Africa. Nature 422, 611-614 (2003).
57. Nabel, G.J. Vaccine for AIDS and Ebola virus infection. Virus Res. 93, 213-217 (2003).
58. Weiss, R.A. HIV and AIDS in relation to other pandemics. EMBO Rep. 4, 510-514 (2003).